Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Other 1

Conditions

Mucositis 4Hematologic Neoplasms 3Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Graft vs Host Disease 1

Interventions

Cyclophosphamide 62Tacrolimus 52Methotrexate 39Mycophenolic Acid 36Busulfan 35fludarabine phosphate 34Cyclosporine 32Antilymphocyte Serum 32fludarabine 28Sirolimus 23Peripheral Blood Stem Cell Transplantation 22Melphalan 22Radiotherapy 21Methylprednisolone 20Whole-Body Irradiation 19Filgrastim 17thymoglobulin 14Thiotepa 10Stem Cell Transplantation 9Granulocyte Colony-Stimulating Factor 9Hematopoietic Stem Cell Transplantation 7Cord Blood Stem Cell Transplantation 7ruxolitinib 6Rituximab 6Etoposide 6Transplantation 5Therapeutics 5Prednisone 5Flow Cytometry 5Cytarabine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Graft vs Host Disease × angiotensin I (1-7) × Other hematologic neoplasm × Clear all
NCT01882387 2016-08-31

Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

Tarix Pharmaceuticals

Phase 2 Withdrawn
OtherOther hematologic neoplasm

Graft vs Host Disease, Hematologic Neoplasms, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡